Showing results (231-240 of 242) with videos related to
Sort By:
Pageof 25
Nature Cancer|June 15, 2023
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLCCaicun Zhou, Ziping Wang, Meili Sun, et al.The New England Journal of Medicine|April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.Thoracic Cancer|September 18, 2018
Chinese multidisciplinary expert consensus: Guidelines on percutaneous transthoracic needle biopsyZhi Guo, Hong Shi, Wentao Li, et al.Future Oncology (London, England)|February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancerPatrick M Forde, Jonathan Spicer, Shun Lu, et al.The Lancet. Oncology|June 16, 2025
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trialCaicun Zhou, Ziping Wang, Meili Sun, et al.Med (New York, N.Y.)|April 12, 2025
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancersKezhong Chen, Anwen Liu, Changli Wang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 24, 2026
Deulorlatinib (TGRX-326) in ALK gene fusion positive non-small cell lung cancer after failure of second-generation inhibitors (DRAGON): a single-arm, multicenter, phase 2 trialJie Huang, Gang Chen, Zhehai Wang, et al.Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|April 5, 2021
[Clinical Recommendations for Perioperative Immunotherapy-induced Adverse Events in Patients with Non-small Cell Lung Cancer]Jun Ni, Miao Huang, Li Zhang, et al.JAMA|January 16, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical TrialShun Lu, Wei Zhang, Lin Wu, et al.Pageof 25